Nicholas J Vogelzang Selected Research

Fluorouracil (Carac)

1/2021	A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.
1/2007	Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.
3/2006	Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: an effective regimen with low toxicity.
10/2003	Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer.
10/2002	A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma.
5/2002	A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nicholas J Vogelzang Research Topics

Disease

112	Prostatic Neoplasms (Prostate Cancer) 04/2023 - 02/2002
85	Neoplasms (Cancer) 01/2023 - 01/2002
54	Renal Cell Carcinoma (Grawitz Tumor) 03/2023 - 02/2002
32	Carcinoma (Carcinomatosis) 01/2022 - 02/2002
25	Neoplasm Metastasis (Metastasis) 06/2018 - 08/2003
20	Disease Progression 01/2022 - 03/2003
16	Leukemia 02/2011 - 02/2002
15	Malignant Mesothelioma 01/2023 - 01/2002
15	Urinary Bladder Neoplasms (Bladder Cancer) 01/2021 - 02/2002
14	Circulating Neoplastic Cells 01/2021 - 06/2009
13	Pain (Aches) 01/2019 - 01/2004
10	Kidney Neoplasms (Kidney Cancer) 03/2023 - 06/2003
10	Neutropenia 01/2020 - 01/2002
8	Fatigue 01/2022 - 01/2004
8	Adenocarcinoma 02/2012 - 02/2003
6	Thrombocytopenia (Thrombopenia) 03/2018 - 02/2002
6	Mesothelioma 01/2017 - 02/2002
6	Transitional Cell Carcinoma 02/2013 - 04/2005
5	Diarrhea 01/2022 - 01/2004
5	Anemia 01/2020 - 05/2003
5	Hypertension (High Blood Pressure) 10/2019 - 05/2010
3	Bone Resorption 04/2023 - 03/2003
3	Melanoma (Melanoma, Malignant) 01/2021 - 09/2011

Drug/Important Bio-Agent (IBA)

42	Hormones (Hormone)IBA 04/2023 - 02/2002
38	AndrogensIBA 04/2023 - 07/2003
34	Docetaxel (Taxotere)FDA Link 07/2022 - 12/2003
27	Prostate-Specific Antigen (Semenogelase)IBA 12/2020 - 04/2002
24	Cisplatin (Platino)FDA LinkGeneric 01/2023 - 02/2002
20	Biomarkers (Surrogate Marker)IBA 04/2023 - 03/2004
14	Gemcitabine FDA Link 01/2021 - 01/2002
11	Tyrosine Kinase InhibitorsIBA 03/2023 - 07/2008
11	Radium-223IBA 10/2022 - 04/2014
11	PlatinumIBA 01/2021 - 09/2010
11	Sunitinib (Sutent)FDA Link 01/2021 - 02/2007
11	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2017 - 12/2002
10	Pemetrexed (MTA)FDA Link 01/2023 - 02/2002
8	Everolimus FDA Link 12/2021 - 06/2013
8	Bevacizumab (Avastin)FDA Link 01/2021 - 06/2006
7	pembrolizumabIBA 01/2022 - 01/2017
7	atezolizumabIBA 01/2021 - 11/2014
7	Sorafenib (BAY 43-9006)FDA Link 01/2017 - 06/2007
7	TOR Serine-Threonine KinasesIBA 01/2016 - 12/2012
7	Methotrexate (Mexate)FDA LinkGeneric 09/2011 - 02/2002
6	Androgen Receptors (Androgen Receptor)IBA 01/2023 - 07/2003
6	Prednisone (Sone)FDA LinkGeneric 01/2022 - 05/2012
6	B7-H1 AntigenIBA 01/2022 - 11/2014
6	Fluorouracil (Carac)FDA LinkGeneric 01/2021 - 05/2002
6	pazopanib FDA Link 01/2020 - 06/2015
6	cabozantinibIBA 01/2019 - 02/2013
6	Proteins (Proteins, Gene)FDA Link 01/2018 - 03/2004
6	Hemoglobins (Hemoglobin)IBA 01/2017 - 04/2002
6	AtrasentanIBA 01/2017 - 02/2003
6	Doxorubicin (Adriamycin)FDA LinkGeneric 09/2011 - 08/2003
6	Suramin (Suramin Sodium)IBA 06/2006 - 07/2002
5	Alkaline PhosphataseIBA 04/2023 - 03/2003
5	VaccinesIBA 01/2023 - 09/2011
5	Paclitaxel (Taxol)FDA LinkGeneric 01/2021 - 06/2003
5	Immune Checkpoint InhibitorsIBA 01/2021 - 01/2015
5	NivolumabIBA 12/2020 - 03/2017
5	Testosterone (Sustanon)FDA Link 12/2020 - 08/2004
5	sipuleucel-T (APC8015)FDA Link 01/2020 - 02/2012
5	Monoclonal AntibodiesIBA 01/2020 - 03/2004
5	Axitinib (AG 013736)IBA 01/2019 - 12/2013
5	Interleukin-2 (IL2)IBA 12/2015 - 05/2002
5	Androgen Antagonists (Antiandrogens)IBA 04/2013 - 07/2003
5	Complementary DNA (cDNA)IBA 02/2012 - 01/2004
5	Vinblastine (Vinblastine Sulfate)FDA Link 09/2011 - 08/2003
4	rucaparibIBA 01/2023 - 01/2020
4	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2023 - 01/2020
4	abirateroneIBA 10/2022 - 10/2012
4	bicalutamide (Casodex)FDA LinkGeneric 10/2022 - 10/2005
4	Angiogenesis InhibitorsIBA 10/2019 - 05/2004
4	Phosphotransferases (Kinase)IBA 01/2019 - 04/2014
4	EnzymesIBA 03/2016 - 01/2004
4	MTOR InhibitorsIBA 11/2014 - 12/2012
4	temsirolimus FDA Link 11/2014 - 06/2007
4	Estramustine FDA Link 05/2011 - 12/2003
4	Ketoconazole (Nizoral)FDA LinkGeneric 11/2007 - 03/2004
4	Cytotoxins (Cytolysins)IBA 10/2005 - 12/2002
3	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 03/2004
3	taxaneIBA 01/2023 - 05/2011
3	enzalutamideIBA 07/2022 - 09/2012
3	lenvatinibIBA 12/2021 - 01/2019
3	vinflunineIBA 01/2021 - 01/2017
3	durvalumabIBA 10/2020 - 03/2017
3	cixutumumabIBA 01/2020 - 05/2015
3	AntigensIBA 01/2020 - 09/2011
3	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2019 - 12/2002
3	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2019 - 01/2017

Therapy/Procedure

97	Therapeutics 04/2023 - 01/2002
60	Castration 04/2023 - 08/2004
47	Drug Therapy (Chemotherapy) 01/2023 - 01/2002
18	Immunotherapy 03/2023 - 02/2004
8	Radiotherapy 05/2017 - 12/2002
5	Nephrectomy 08/2019 - 02/2004
5	Neoadjuvant Therapy 07/2014 - 08/2003
5	Cystectomy 01/2014 - 08/2003
4	Aftercare (After-Treatment) 01/2023 - 11/2004
4	Prostatectomy (Retropubic Prostatectomy) 01/2018 - 02/2007
4	Combination Drug Therapy (Combination Chemotherapy) 09/2011 - 06/2003